Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Merck & Co. Inc., solvency ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The solvency position, as indicated by the provided ratios, exhibits a generally stable pattern with some fluctuations over the observed period. Throughout 2022, a consistent, albeit modest, decline in leverage metrics is apparent. This trend reverses in the first half of 2023, with a noticeable increase in debt-related ratios, before stabilizing and showing some decline again towards the end of 2024. The final period observed into the first half of 2025 shows a slight increase in some ratios.

Debt to Equity
The debt to equity ratio decreased steadily from 0.78 in March 2022 to 0.66 in March 2023. A significant increase is then observed, reaching 0.95 in June 2023, before declining to 0.80 by December 2024. The ratio remains relatively stable in the first half of 2025, at 0.72 and 0.80 respectively, before increasing to 0.94 by December 2025. This suggests periods of increased reliance on debt financing followed by deleveraging.
Debt to Capital
The debt to capital ratio mirrors the trend of the debt to equity ratio, decreasing from 0.44 in March 2022 to 0.40 in December 2022. It then rises to 0.49 in June 2023, followed by a period of relative stability between 0.46 and 0.48 through December 2023. A slight decline to 0.42 is observed in the first half of 2024, and the ratio increases to 0.48 by December 2025.
Debt to Assets
The debt to assets ratio demonstrates a similar pattern, declining from 0.30 in March 2022 to 0.28 in September 2022, and remaining at 0.28 through December 2022. An increase to 0.35 is seen in June 2023, followed by stabilization around 0.33-0.34. The ratio decreases to 0.30 in March 2025, before increasing to 0.36 by December 2025.
Financial Leverage
Financial leverage, as measured by this ratio, decreased from 2.61 in March 2022 to 2.30 in March 2023. A subsequent increase to 2.84 is observed by December 2023, before decreasing to 2.53 by December 2024. The ratio then increases again, reaching 2.60 by December 2025. This indicates fluctuations in the company’s ability to utilize debt to generate returns.

Overall, the observed solvency ratios suggest a dynamic capital structure. While the company generally maintained a stable solvency position, the increases in debt ratios during portions of 2023 and 2025 warrant further investigation to understand the underlying drivers and potential implications for financial risk.


Debt Ratios


Debt to Equity

Merck & Co. Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Loans payable and current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The debt to equity ratio exhibits fluctuations over the observed period, generally indicating a shifting balance between the company’s reliance on debt versus equity financing. An initial downward trend is followed by an increase, then a period of relative stability, and a final increase.

Initial Decline (Mar 31, 2022 – Dec 31, 2022)
From March 31, 2022, to December 31, 2022, the debt to equity ratio decreased from 0.78 to 0.67. This suggests a strengthening of the company’s financial position through either a reduction in debt or an increase in stockholders’ equity, or a combination of both. The decrease, while present, is relatively gradual.
Increase and Volatility (Mar 31, 2023 – Sep 30, 2023)
The ratio experienced a significant increase to 0.95 by June 30, 2023, indicating increased leverage. This was followed by a decrease to 0.85 by September 30, 2023. This period demonstrates increased volatility in the capital structure, potentially due to debt issuance or equity buybacks. Total debt increased substantially during this period, while equity decreased.
Relative Stability (Dec 31, 2023 – Sep 30, 2025)
From December 31, 2023, through September 30, 2025, the debt to equity ratio remained relatively stable, fluctuating between 0.80 and 0.94. This suggests a period of more consistent capital structure management. While fluctuations occurred, they were less pronounced than in the prior period.
Final Increase (Dec 31, 2025)
The ratio concluded the period with a notable increase to 0.94 on December 31, 2025. This is the highest value observed throughout the analyzed timeframe, indicating a greater reliance on debt financing at the end of the period. Total debt increased significantly, while equity remained relatively flat.
Overall Trend
Overall, the debt to equity ratio demonstrates a U-shaped trend. It begins with a decline, experiences a period of volatility and increase, stabilizes for a time, and then concludes with a final increase. This suggests a dynamic capital structure influenced by financing decisions and potentially strategic investments or acquisitions.

Debt to Capital

Merck & Co. Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Loans payable and current portion of long-term debt
Long-term debt, excluding current portion
Total debt
Total Merck & Co., Inc. stockholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The debt to capital ratio exhibits a generally fluctuating pattern over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrates a decreasing trend, followed by an increase, and then a period of relative stability before concluding with another increase.

Initial Decreasing Trend (Mar 31, 2022 – Dec 31, 2022)
From March 31, 2022, to December 31, 2022, the debt to capital ratio declined from 0.44 to 0.40. This indicates a decreasing reliance on debt financing relative to the company’s total capital structure during this timeframe. The reduction suggests either a decrease in debt levels or an increase in capital, or a combination of both.
Subsequent Increase (Mar 31, 2023 – Jun 30, 2023)
The ratio experienced a notable increase from 0.40 in March 2023 to 0.49 in June 2023. This suggests a significant increase in debt relative to capital during this short period. The increase in total debt, as evidenced by the underlying figures, is the primary driver of this change.
Period of Relative Stability (Sep 30, 2023 – Mar 31, 2025)
Following the peak in June 2023, the debt to capital ratio fluctuated within a relatively narrow range, between 0.44 and 0.46, through March 31, 2025. This suggests a period of more consistent capital structure management, with debt and capital moving in a somewhat synchronized manner. While fluctuations occurred, they were less pronounced than the earlier increase.
Final Increase (Jun 30, 2025 – Dec 31, 2025)
The ratio increased again, reaching 0.48 by June 30, 2025, and further increasing to 0.48 by December 31, 2025. This final increase indicates a renewed reliance on debt financing as a proportion of total capital. The substantial increase in total debt during this period is the primary contributor to this change.

Overall, the observed pattern suggests a dynamic capital structure. While the company initially reduced its debt-to-capital ratio, it subsequently increased it, demonstrating a willingness to utilize debt financing, particularly in the latter part of the observed period. The fluctuations indicate active management of the capital structure, potentially in response to investment opportunities or changing financial conditions.


Debt to Assets

Merck & Co. Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Loans payable and current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The debt-to-assets ratio for the analyzed period demonstrates a generally stable pattern with some fluctuations. Initially, the ratio remained consistent at 0.30 for the first two quarters, before decreasing slightly to 0.28 in the third quarter. It then stabilized around 0.28 to 0.29 for the remainder of 2022.

A noticeable increase in the ratio occurred in the first half of 2023, rising from 0.29 to 0.35. This suggests an increased reliance on debt financing relative to assets during this period. Subsequently, the ratio decreased to 0.33 and remained at that level through the end of 2023. The first half of 2024 saw a slight increase to 0.34, followed by a return to 0.32 for the subsequent two quarters.

The latter part of the analyzed period exhibits a more pronounced upward trend. The ratio increased from 0.30 in the first quarter of 2025 to 0.32 in the second quarter, and further to 0.36 by the end of 2025. This indicates a growing proportion of debt financing relative to total assets in the most recent quarters.

Overall Trend
The debt-to-assets ratio generally fluctuated between 0.28 and 0.35 throughout the period. While relatively stable for much of the time, a clear upward trend emerges in the final quarters of the analysis, suggesting a potential shift in the company’s capital structure.
Short-Term Fluctuations
The most significant short-term fluctuation was the increase from 0.29 to 0.35 between the first and second quarters of 2023. This warrants further investigation to understand the specific factors driving the increased leverage during that period.
Long-Term Trend
The long-term trend shows a moderate increase in the ratio, particularly evident in the final year of the analyzed period. This could be due to increased investment in assets funded by debt, or a decrease in asset values. Continued monitoring is recommended to assess the sustainability of this trend.
Ratio Range
The ratio remained within a range of 0.28 to 0.36. A ratio above 0.30 suggests a moderate level of debt financing, and the recent increase to 0.36 indicates a potentially higher risk profile, depending on the industry and company-specific factors.

Financial Leverage

Merck & Co. Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Total assets
Total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial leverage ratio for the analyzed period demonstrates a generally decreasing trend, with some fluctuations. Initially, the ratio exhibited a decline from 2.61 to 2.37 between March 31, 2022, and December 31, 2022. A subsequent increase was observed through December 31, 2023, peaking at 2.84 before resuming a downward trajectory. The most recent periods show a slight increase, concluding at 2.60 as of December 31, 2025.

Overall Trend
The overall trend indicates a moderate level of financial leverage. While fluctuations exist, the ratio generally decreased from the beginning of the period to the end, suggesting a reduction in the proportion of assets financed by equity. The recent uptick warrants monitoring.
Initial Decline (Mar 31, 2022 – Dec 31, 2022)
A consistent decrease in the financial leverage ratio occurred during this period. This suggests the company was reducing its reliance on debt financing relative to equity, potentially through debt repayment or increased equity contributions.
Subsequent Increase (Dec 31, 2022 – Dec 31, 2023)
The ratio increased from 2.37 to 2.84. This could be attributed to an increase in debt, a decrease in equity, or a combination of both. Further investigation into the underlying changes in total assets, stockholders’ equity, and debt levels would be necessary to determine the specific drivers.
Recent Fluctuations (Dec 31, 2023 – Dec 31, 2025)
The ratio decreased from 2.84 to 2.50, then increased to 2.60. These fluctuations suggest a dynamic capital structure. The increase in the most recent period could indicate renewed borrowing or a decrease in equity, requiring further scrutiny.
Relationship to Total Assets and Equity
Total assets remained relatively stable throughout the period, with a noticeable increase towards the end. Total stockholders’ equity experienced a decrease in the middle of the period, followed by a recovery and subsequent growth. The interplay between these two factors significantly influences the financial leverage ratio.

In conclusion, the company’s financial leverage has shown a generally decreasing trend, punctuated by periods of increase. The recent increase in the ratio should be monitored to assess its potential impact on the company’s financial risk profile.